呼吸器合胞体ウイルス（RSV）治療薬の世界市場レポート 2025年

呼吸器合胞体ウイルス（RSV）治療薬市場規模は、今後数年で飛躍的な成長が見込まれます。2029年にはCAGR23.1％で45億9,000万米ドルに成長します。予測期間の成長は、生物学的療法の革新、新たな抗ウイルス剤、高齢者人口への注力、妊産婦の予防接種戦略、世界の共同研究などに起因すると考えられます。予測期間における主な動向には、モノクローナル抗体の進歩、経鼻ワクチンとデリバリーシステム、併用療法、新規ドラッグデリバリーシステム、在宅治療オプションなどがあります。

政府のイニシアチブと資金提供の増加も、今後の呼吸器合胞体ウイルス（RSV）治療薬市場の成長を後押ししています。RSV治療薬の開発に対する政府やヘルスケア組織の支援は、特に乳幼児や高齢者などの脆弱な集団におけるRSVに関連する入院、重症感染症、医療費の大きな負担を軽減する必要性によって動機づけられています。政府のプログラムは、研究への資金提供、迅速承認のような規制上の優遇措置、および認識を促進し、早期診断と治療を奨励する公衆衛生キャンペーンを通じて、RSV治療薬分野の拡大に貢献しています。例えば、英国政府は2024年9月、乳幼児と高齢者の両方を保護する世界初の全国的RSVワクチン接種プログラムを開始しました。このプログラムには、新生児を守るための28週以降の妊婦へのワクチン、75歳以上の定期プログラム、75歳から79歳までの単発キャンペーンが含まれます。イングランド、ウェールズ、北アイルランドでは9月から、スコットランドでは8月12日から開始されます。このように、政府のイニシアティブと資金提供の増加が、呼吸器合胞体ウイルス（RSV）治療薬市場の成長を後押ししています。

疾病率の上昇は、呼吸器合胞体ウイルス（RSV）治療薬市場の成長軌道を後押しする重要な要因です。疾患とは、感染、遺伝的異常、環境ストレスなどさまざまな原因により、生物の一部、臓器、システムに影響を及ぼす病的状態を意味します。一般的な呼吸器ウイルスであるRSVは、幅広い年齢層に影響を及ぼしており、特に乳幼児や高齢者のような感染しやすい層で感染率が急増していることから、効果的な治療介入が急務となっています。例えば、クリーブランド・クリニックが2023年に発表したデータによると、米国では年間推定57,000人の5歳未満の小児がRSVによる入院を必要としています。その結果、疾病率の上昇が呼吸器合胞体ウイルス（RSV）治療薬市場拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界呼吸器合胞体ウイルス（RSV）治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場：成長率分析
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場の実績：規模と成長, 2019-2024
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界呼吸器合胞体ウイルス（RSV）治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• パリビズマブ
• リバビリン
• その他の薬物
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫予防
• 支持療法
• 抗ウイルス薬
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射可能
• その他の剤形
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場患者タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 大人
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場、パリビズマブの薬剤別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場リバビリンの薬剤別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ウイルス薬
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場、その他の医薬品のサブセグメンテーション、医薬品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シドフォビル
• ニタゾキサニド
• その他の実験的または適応外治療

第7章 地域別・国別分析

• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の呼吸器合胞体ウイルス（RSV）治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 呼吸器合胞体ウイルス（RSV）治療薬市場：競合情勢
• 呼吸器合胞体ウイルス（RSV）治療薬市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline plc.
• Gilead Sciences Inc.
• Moderna Inc.
• Regeneron Pharmaceuticals Inc.
• Novavax AB
• Vir Biotechnology Inc.
• Lupin Limited
• Kyorin Pharmaceutical Co. Ltd.
• Bavarian Nordic A/S
• SciClone Pharmaceuticals Inc.
• Enanta Pharmaceuticals Inc.
• Hetero Healthcare Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 呼吸器合胞体ウイルス（RSV）治療薬市場2029：新たな機会を提供する国
• 呼吸器合胞体ウイルス（RSV）治療薬市場2029：新たな機会を提供するセグメント
• 呼吸器合胞体ウイルス（RSV）治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Respiratory syncytial virus (RSV) therapeutics include various treatments and medications designed to manage and treat infections caused by the respiratory syncytial virus. This virus is known to cause respiratory illness, ranging from mild to severe, with higher risks for infants, young children, older adults, and individuals with weakened immune systems.

The main categories of drugs in respiratory syncytial virus (RSV) therapeutics encompass palivizumab, ribavirin, and others. Palivizumab, a monoclonal antibody developed through DNA recombination, is utilized for respiratory infections in children to prevent complications arising from respiratory syncytial virus infection. Treatments are further classified into immune prophylaxis, supportive care, and antiviral medications, available in various dosage forms such as oral, injectable, and others. These therapeutics are accessible through channels including hospital pharmacies, retail pharmacies, and online pharmacies, catering to patients ranging from pediatrics to adults.

The respiratory syncytial virus (RSV) therapeutics research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus (RSV) therapeutics market statistics, including the respiratory syncytial virus (RSV) therapeutics industry's global market size, regional shares, competitors with a respiratory syncytial virus (RSV) therapeutics market share, detailed respiratory syncytial virus (RSV) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus (RSV) therapeutics industry. This respiratory syncytial virus (RSV) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The respiratory syncytial virus (RSV) therapeutics market size has grown exponentially in recent years. It will grow from $1.6 billion in 2024 to $2 billion in 2025 at a compound annual growth rate (CAGR) of 25.0%. The growth in the historic period can be attributed to disease awareness, advancements in virology, pediatric vulnerability, epidemic outbreaks, vaccine development

The respiratory syncytial virus (RSV) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $4.59 billion in 2029 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to biologic therapies innovation, emerging antivirals, focus on elderly population, maternal immunization strategies, global research collaborations. Major trends in the forecast period include monoclonal antibodies advancements, nasal vaccines and delivery systems, combination therapies, novel drug delivery systems, home-based treatment options.

The rise in government initiatives and funding is also driving the growth of the respiratory syncytial virus (RSV) therapeutics market in the future. Government and healthcare organization support for the development of RSV therapeutics is motivated by the need to alleviate the significant burden of hospitalizations, severe infections, and healthcare costs associated with RSV, particularly among vulnerable populations such as infants and the elderly. Government programs contribute to the expansion of the RSV therapeutics sector through funding for research, regulatory incentives like fast-track approvals, and public health campaigns that promote awareness and encourage early diagnosis and treatment. For instance, in September 2024, the UK Government launched the world's first national RSV vaccination program to protect both infants and older adults. This program includes vaccines for pregnant women beyond 28 weeks to safeguard newborns, a routine program for those over 75, and a one-off campaign for individuals aged 75 to 79. It aims to alleviate winter pressure on the NHS. Rollouts are set to begin in England, Wales, and Northern Ireland in September, with Scotland starting on August 12. Thus, the increase in government initiatives and funding is propelling the growth of the respiratory syncytial virus (RSV) therapeutics market.

The rising rate of disease is a key factor propelling the growth trajectory of the respiratory syncytial virus (RSV) therapeutics market. A disease signifies a pathological condition affecting a part, organ, or system of an organism due to various causes, including infection, genetic anomalies, or environmental stressors. Given RSV's widespread impact as a common respiratory virus affecting individuals across age groups, the surge in infection rates, particularly among vulnerable demographics such as infants and the elderly, underscores the urgent need for effective therapeutic interventions. For example, according to data released by the Cleveland Clinic in 2023, an estimated 57,000 children under 5 years require hospitalization annually in the U.S. due to RSV. Consequently, the escalating disease rate is a driving force behind the expansion of the respiratory syncytial virus (RSV) therapeutics market.

Developing more effective drugs and vaccines stands as a prominent trend gaining traction within the respiratory syncytial virus (RSV) therapeutics market. Key companies operating in this domain are dedicating their efforts towards creating innovative drugs and vaccines to maintain their market presence. For instance, in May 2023, Pfizer Inc., a renowned pharmaceutical manufacturer in the United States, secured approval from the Food and Drug Administration (FDA), a federal agency responsible for safeguarding public health, for ABRYSVO. This bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine), is administered to prevent lower respiratory tract illnesses caused by RSV in individuals aged 60 and above. ABRYSVO, an unadjuvanted vaccine containing a pair of preF proteins designed to enhance immunity against RSV A and B strains, has demonstrated both safety and efficacy in clinical trials.

Strategic collaborations are emerging as a significant trend gaining momentum within the respiratory syncytial virus (RSV) therapeutics market. Leading companies within this sector are prioritizing the establishment of strategic partnerships to fortify their market positions. For example, in 2023, the Cyrus Poonawalla Group, an India-based biotechnology firm, teamed up with the Serum Institute of India, a prominent biotechnology company specializing in vaccine production, to receive official regulatory clearance for a versatile vaccine. This groundbreaking vaccine aims to combat a wide spectrum of diseases, encompassing polio, tetanus, diphtheria, hepatitis B, mumps, measles, and rubella.

In June 2022, Pfizer Inc., a US-based pharmaceutical manufacturing company, successfully completed the acquisition of ReViral Limited for an undisclosed amount. This strategic move is part of Pfizer's efforts to enhance its pipeline of promising treatment candidates, with a particular focus on sisunatovir. Sisunatovir is an oral antagonist developed to prevent the fusion of the respiratory syncytial virus (RSV) with the host cell. ReViral Limited, headquartered in the UK, is a clinical-stage biotechnology company that specializes in the development of medications targeting RSV.

Major companies operating in the respiratory syncytial virus (RSV) therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Regeneron Pharmaceuticals Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd

North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (rsv) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the respiratory syncytial virus (rsv) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The respiratory syncytial virus (RSV) therapeutics market includes revenues earned by entities by providing services such as home care and respiratory support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory syncytial virus (RSV) therapeutics market consists of sales of antiviral drugs, monoclonal antibodies, and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respiratory syncytial virus (rsv) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory syncytial virus (rsv) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory syncytial virus (rsv) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug: Palivizumab; Ribavirin; Other Drugs
• 2) By Treatment: Immune Prophylaxis; Supportive Care; Antiviral Medications
• 3) By Dosage Form: Oral; Injectable; Other Dosage Forms
• 4) By Patient Type: Pediatrics; Adults
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Palivizumab: Monoclonal Antibody
• 2) By Ribavirin: Antiviral Medication
• 3) By Other Drugs: Cidofovir; Nitazoxanide; Other Experimental Or Off-Label Treatments
• Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Respiratory Syncytial Virus (RSV) Therapeutics Market Characteristics

3. Respiratory Syncytial Virus (RSV) Therapeutics Market Trends And Strategies

4. Respiratory Syncytial Virus (RSV) Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Respiratory Syncytial Virus (RSV) Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Respiratory Syncytial Virus (RSV) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Growth Rate Analysis
• 5.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Respiratory Syncytial Virus (RSV) Therapeutics Total Addressable Market (TAM)

6. Respiratory Syncytial Virus (RSV) Therapeutics Market Segmentation

• 6.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Palivizumab
• Ribavirin
• Other Drugs
• 6.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immune Prophylaxis
• Supportive Care
• Antiviral Medications
• 6.3. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Dosage Forms
• 6.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• 6.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Sub-Segmentation Of Palivizumab, By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibody
• 6.7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Sub-Segmentation Of Ribavirin, By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Medication
• 6.8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Sub-Segmentation Of Other Drugs, By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cidofovir
• Nitazoxanide
• Other Experimental Or Off-Label Treatments

7. Respiratory Syncytial Virus (RSV) Therapeutics Market Regional And Country Analysis

• 7.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market

• 8.1. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Respiratory Syncytial Virus (RSV) Therapeutics Market

• 9.1. China Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 9.2. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Respiratory Syncytial Virus (RSV) Therapeutics Market

• 10.1. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market

• 11.1. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 11.2. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market

• 12.1. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market

• 13.1. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market

• 14.1. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 14.2. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market

• 15.1. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 15.2. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Respiratory Syncytial Virus (RSV) Therapeutics Market

• 16.1. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market

• 17.1. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Respiratory Syncytial Virus (RSV) Therapeutics Market

• 18.1. France Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market

• 19.1. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market

• 20.1. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market

• 21.1. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 21.2. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market

• 22.1. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Respiratory Syncytial Virus (RSV) Therapeutics Market

• 23.1. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 23.2. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Respiratory Syncytial Virus (RSV) Therapeutics Market

• 24.1. USA Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 24.2. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market

• 25.1. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 25.2. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Respiratory Syncytial Virus (RSV) Therapeutics Market

• 26.1. South America Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 26.2. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market

• 27.1. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market

• 28.1. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 28.2. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market

• 29.1. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
• 29.2. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape
• 30.2. Respiratory Syncytial Virus (RSV) Therapeutics Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Respiratory Syncytial Virus (RSV) Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca PLC
• 31.3. Abbott Laboratories
• 31.4. GlaxoSmithKline plc.
• 31.5. Gilead Sciences Inc.
• 31.6. Moderna Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Novavax AB
• 31.9. Vir Biotechnology Inc.
• 31.10. Lupin Limited
• 31.11. Kyorin Pharmaceutical Co. Ltd.
• 31.12. Bavarian Nordic A/S
• 31.13. SciClone Pharmaceuticals Inc.
• 31.14. Enanta Pharmaceuticals Inc.
• 31.15. Hetero Healthcare Ltd

32. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Respiratory Syncytial Virus (RSV) Therapeutics Market

34. Recent Developments In The Respiratory Syncytial Virus (RSV) Therapeutics Market

35. Respiratory Syncytial Virus (RSV) Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Respiratory Syncytial Virus (RSV) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Respiratory Syncytial Virus (RSV) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Respiratory Syncytial Virus (RSV) Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer